HAEMONETICS CORP/MASS (HAE) Stock Fundamental Analysis
USA - NYSE:HAE - US4050241003 - Common Stock
49.95 USD
-1.07 (-2.1%)
49.95 USD
0 (0%)
Taking everything into account, HAE scores 5 out of 10 in our fundamental rating. HAE was compared to 191 industry peers in the Health Care Equipment & Supplies industry. While HAE belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. HAE may be a bit undervalued, certainly considering the very reasonable score on growth
1. Profitability
1.1 Basic Checks
HAE had positive earnings in the past year.
In the past year HAE had a positive cash flow from operations.
In the past 5 years HAE has always been profitable.
Each year in the past 5 years HAE had a positive operating cash flow.
1.2 Ratios
HAE's Return On Assets of 6.63% is amongst the best of the industry. HAE outperforms 86.91% of its industry peers.
The Return On Equity of HAE (18.51%) is better than 93.19% of its industry peers.
HAE has a better Return On Invested Capital (9.88%) than 90.58% of its industry peers.
HAE had an Average Return On Invested Capital over the past 3 years of 8.96%. This is in line with the industry average of 8.46%.
The last Return On Invested Capital (9.88%) for HAE is above the 3 year average (8.96%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.63% | ||
| ROE | 18.51% | ||
| ROIC | 9.88% |
ROA(3y)6.05%
ROA(5y)4.97%
ROE(3y)15.59%
ROE(5y)12.69%
ROIC(3y)8.96%
ROIC(5y)7.22%
1.3 Margins
Looking at the Profit Margin, with a value of 12.13%, HAE belongs to the top of the industry, outperforming 87.96% of the companies in the same industry.
In the last couple of years the Profit Margin of HAE has grown nicely.
The Operating Margin of HAE (18.12%) is better than 89.01% of its industry peers.
In the last couple of years the Operating Margin of HAE has remained more or less at the same level.
HAE has a Gross Margin (57.42%) which is in line with its industry peers.
HAE's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 18.12% | ||
| PM (TTM) | 12.13% | ||
| GM | 57.42% |
OM growth 3Y21.18%
OM growth 5Y0.48%
PM growth 3Y41.28%
PM growth 5Y9.75%
GM growth 3Y1.97%
GM growth 5Y2.6%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so HAE is still creating some value.
The number of shares outstanding for HAE has been reduced compared to 1 year ago.
The number of shares outstanding for HAE has been reduced compared to 5 years ago.
Compared to 1 year ago, HAE has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.20 indicates that HAE is not a great score, but indicates only limited risk for bankruptcy at the moment.
HAE has a Altman-Z score of 2.20. This is in the better half of the industry: HAE outperforms 64.40% of its industry peers.
HAE has a debt to FCF ratio of 7.62. This is a slightly negative value and a sign of low solvency as HAE would need 7.62 years to pay back of all of its debts.
HAE has a better Debt to FCF ratio (7.62) than 76.44% of its industry peers.
A Debt/Equity ratio of 1.04 is on the high side and indicates that HAE has dependencies on debt financing.
HAE has a worse Debt to Equity ratio (1.04) than 78.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.04 | ||
| Debt/FCF | 7.62 | ||
| Altman-Z | 2.2 |
ROIC/WACC1.52
WACC6.48%
2.3 Liquidity
A Current Ratio of 1.72 indicates that HAE should not have too much problems paying its short term obligations.
HAE has a worse Current ratio (1.72) than 69.63% of its industry peers.
A Quick Ratio of 1.04 indicates that HAE should not have too much problems paying its short term obligations.
HAE's Quick ratio of 1.04 is on the low side compared to the rest of the industry. HAE is outperformed by 74.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.72 | ||
| Quick Ratio | 1.04 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 17.72% over the past year.
Measured over the past 5 years, HAE shows a small growth in Earnings Per Share. The EPS has been growing by 6.66% on average per year.
Looking at the last year, HAE shows a small growth in Revenue. The Revenue has grown by 0.91% in the last year.
The Revenue has been growing slightly by 6.60% on average over the past years.
EPS 1Y (TTM)17.72%
EPS 3Y20.84%
EPS 5Y6.66%
EPS Q2Q%7.84%
Revenue 1Y (TTM)0.91%
Revenue growth 3Y11.07%
Revenue growth 5Y6.6%
Sales Q2Q%-4.4%
3.2 Future
Based on estimates for the next years, HAE will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.55% on average per year.
HAE is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.99% yearly.
EPS Next Y6.62%
EPS Next 2Y10.13%
EPS Next 3Y10.55%
EPS Next 5YN/A
Revenue Next Year-4.73%
Revenue Next 2Y0.73%
Revenue Next 3Y2.99%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 10.74 indicates a reasonable valuation of HAE.
Based on the Price/Earnings ratio, HAE is valued cheaply inside the industry as 92.15% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 27.20. HAE is valued rather cheaply when compared to this.
Based on the Price/Forward Earnings ratio of 9.01, the valuation of HAE can be described as reasonable.
Compared to the rest of the industry, the Price/Forward Earnings ratio of HAE indicates a rather cheap valuation: HAE is cheaper than 93.72% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.71. HAE is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.74 | ||
| Fwd PE | 9.01 |
4.2 Price Multiples
HAE's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. HAE is cheaper than 91.62% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, HAE is valued cheaper than 91.10% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.97 | ||
| EV/EBITDA | 9.44 |
4.3 Compensation for Growth
HAE's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
HAE has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)1.62
PEG (5Y)1.61
EPS Next 2Y10.13%
EPS Next 3Y10.55%
5. Dividend
5.1 Amount
HAE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
49.95
-1.07 (-2.1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners118.25%
Inst Owner Change-2.81%
Ins Owners1.14%
Ins Owner Change9.02%
Market Cap2.41B
Analysts81.33
Price Target81.91 (63.98%)
Short Float %7.7%
Short Ratio3.87
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.91%
Min EPS beat(2)0.62%
Max EPS beat(2)7.2%
EPS beat(4)4
Avg EPS beat(4)2.96%
Min EPS beat(4)0.62%
Max EPS beat(4)7.2%
EPS beat(8)7
Avg EPS beat(8)4%
EPS beat(12)11
Avg EPS beat(12)9.1%
EPS beat(16)14
Avg EPS beat(16)8.76%
Revenue beat(2)1
Avg Revenue beat(2)1.96%
Min Revenue beat(2)-0.63%
Max Revenue beat(2)4.55%
Revenue beat(4)1
Avg Revenue beat(4)0.38%
Min Revenue beat(4)-2.22%
Max Revenue beat(4)4.55%
Revenue beat(8)4
Avg Revenue beat(8)1.08%
Revenue beat(12)8
Avg Revenue beat(12)2.33%
Revenue beat(16)10
Avg Revenue beat(16)1.82%
PT rev (1m)-13.84%
PT rev (3m)-12.51%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5.48%
EPS NY rev (1m)-0.85%
EPS NY rev (3m)-1.45%
Revenue NQ rev (1m)-0.18%
Revenue NQ rev (3m)-2.97%
Revenue NY rev (1m)-1.13%
Revenue NY rev (3m)-1.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.74 | ||
| Fwd PE | 9.01 | ||
| P/S | 1.79 | ||
| P/FCF | 14.97 | ||
| P/OCF | 10.62 | ||
| P/B | 2.73 | ||
| P/tB | N/A | ||
| EV/EBITDA | 9.44 |
EPS(TTM)4.65
EY9.31%
EPS(NY)5.54
Fwd EY11.1%
FCF(TTM)3.34
FCFY6.68%
OCF(TTM)4.7
OCFY9.41%
SpS27.94
BVpS18.31
TBVpS-3.65
PEG (NY)1.62
PEG (5Y)1.61
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.63% | ||
| ROE | 18.51% | ||
| ROCE | 12.63% | ||
| ROIC | 9.88% | ||
| ROICexc | 11.65% | ||
| ROICexgc | 32.9% | ||
| OM | 18.12% | ||
| PM (TTM) | 12.13% | ||
| GM | 57.42% | ||
| FCFM | 11.95% |
ROA(3y)6.05%
ROA(5y)4.97%
ROE(3y)15.59%
ROE(5y)12.69%
ROIC(3y)8.96%
ROIC(5y)7.22%
ROICexc(3y)10.46%
ROICexc(5y)8.47%
ROICexgc(3y)26.78%
ROICexgc(5y)22.33%
ROCE(3y)11.45%
ROCE(5y)9.23%
ROICexcg growth 3Y22.36%
ROICexcg growth 5Y7.33%
ROICexc growth 3Y21.7%
ROICexc growth 5Y-5.09%
OM growth 3Y21.18%
OM growth 5Y0.48%
PM growth 3Y41.28%
PM growth 5Y9.75%
GM growth 3Y1.97%
GM growth 5Y2.6%
F-Score8
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.04 | ||
| Debt/FCF | 7.62 | ||
| Debt/EBITDA | 2.56 | ||
| Cap/Depr | 57.06% | ||
| Cap/Sales | 4.88% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 63.09% | ||
| Profit Quality | 98.45% | ||
| Current Ratio | 1.72 | ||
| Quick Ratio | 1.04 | ||
| Altman-Z | 2.2 |
F-Score8
WACC6.48%
ROIC/WACC1.52
Cap/Depr(3y)79.52%
Cap/Depr(5y)76.24%
Cap/Sales(3y)6.31%
Cap/Sales(5y)6.58%
Profit Quality(3y)103.91%
Profit Quality(5y)115.34%
High Growth Momentum
Growth
EPS 1Y (TTM)17.72%
EPS 3Y20.84%
EPS 5Y6.66%
EPS Q2Q%7.84%
EPS Next Y6.62%
EPS Next 2Y10.13%
EPS Next 3Y10.55%
EPS Next 5YN/A
Revenue 1Y (TTM)0.91%
Revenue growth 3Y11.07%
Revenue growth 5Y6.6%
Sales Q2Q%-4.4%
Revenue Next Year-4.73%
Revenue Next 2Y0.73%
Revenue Next 3Y2.99%
Revenue Next 5YN/A
EBIT growth 1Y18.51%
EBIT growth 3Y34.59%
EBIT growth 5Y7.12%
EBIT Next Year34.55%
EBIT Next 3Y15.63%
EBIT Next 5YN/A
FCF growth 1Y-8.53%
FCF growth 3Y16.98%
FCF growth 5Y2.09%
OCF growth 1Y-9.46%
OCF growth 3Y1.79%
OCF growth 5Y2.81%